Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...

Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trials ...